new models of innovation in life sciences - mars market insights
Post on 25-Jan-2015
1.623 Views
Preview:
DESCRIPTION
TRANSCRIPT
Pfizer Canada To Be Truly Healthy, It Takes More Than Medication
Innovation Gap
! “We intend to make our internal capability even more effective by tapping into the best scientific capability outside of our walls -wherever it exists. That’s why we are reaching out to scientists around the world.” Jeff Kindler, CEO, Pfizer
Innovation Gap
Understanding Disease Biology is not a Competitive Activity
Canadian Public-Private Partnership Models of Innovation
Collaborative R&D Partnerships Centers of Excellence in Commercialization (CECRs) Quebec Pain Research Network (QPRN) Ontario Institute of Cancer Research (OICR) Center for Drug Research & Discovery (CDRD)
Pre-Competitive R&D Partnerships Quebec Drug Discovery Consortium (CQDM) Structural Genomics Consortium (SGC)
Partnership Models of Innovation Pre-Competitive Competitive
IRMA : THE DRUG REPOSITIONING
INITIATIVE
World class science drives the day…… Very significant internal competition for global R&D $$s
Local affiliates can drive internal global recognition of local opportunities, through local resources and local funds.
Alignment with large consortia and public funding is very helpful
In the Future Public-Private and Pre-competitive research is growing ON is in position to excel in this emerging paradigm
Public support of PPP is not a temporary concept. Funding must be maintained, as a basis for attracting other $$s into the project.
Canadian Public-Private Partnership Models of Innovation
Slide 1
Enable Integrate Engage
A New Model for the Translation of Regenerative Medicine: Collaborative, Capital-Efficient Technology Development
New Models of Innovation in Life Sciences
April 20th, 2011, MaRS, Toronto
Michael H. May PhD CEO
Slide 2
“Open Innovation” is Not New
Non-Zero-Sum Gain
“NONZERO – The Logic of Human Destiny”, Robert Wright
Collaboration
Technology
Environmental Stress or Need
Open Innovation
Zero-Sum Gain
Competition
Slide 3
Funding of Research and Commercialization in Canada
Slide 4
CCRM Builds on MaRS and MI
!"#$%&'()'*%&#+!#,-..-*%#/%%)/..0#*%#123#
Slide 5
A Global Nexus for RM Technology and Commercialization
Mission: To bridge the RM commercialization gap by leveraging funding and infrastructure,
and mobilizing business and scientific expertise to translate technologies
Product Development Basic R&D
Pre-Commercial Validation
Clinical & Commercial Validation
Existing Government
Programs
Industry Investment
Capital
Slide 6
Enable Product Development
Integrate Science and Business
Create Links to Market
Our Plan to Bridge the RM Commercialization Gap
Existing Government
Programs
Industry Investment
Capital
Slide 7
Translation through Collaboration
Slide 8
capital efficient RM development
utilize academic infrastructure facilitate global collaboration
focus on key bottlenecks explore alternative funding sources
Slide 9
Slide 10
Industry Engagement Platform 1 Platform 2 Platform 3 4 companies, 2
Canadian, 2 large and 3 small
6 companies, 2 Canadian, 3 large
and 3 small
6 companies, 2 Canadian, 1 large
and 5 small
Foundational Reagents, tools and processes
Community Offerings Market Needs
! Cell culture bioprocesses, sensors and scale-up / out
Clinical and commercial quantities of stem/differentiated
cells
! iPSC cells ! Lineage reprogramming ! Stem cell characterization
and standardization
Characterized and validated stem cell lines
! Biomaterials/biocompatibility ! Therapeutic polymers ! Microfabrication ! Functional and stabilized,
cell-derived tissues
Tissue mimetics for drug screening & transplantation
Slide 11
Driving Open Innovation
Non-Zero-Sum Gain
Zero-Sum Gain
Collaboration
Technology
Environmental Stress or Need
" Capital efficient " Pre-competitive
evidence-based infection control
!"
Evidence-based Infection Control!#$%"&'(')*+",-./0')$%"1%'0-*"'*2-34)*"3)*5%)6"$('*7"7-)(8/4/6"/*/6943(:"5)";)*'5)%:";-/($%-:"/*1"';8%)0-")$53);-(<"
#$%"=)/6+">-68"/3.'-0-"/*1"-?3--1"8/4-*5"(/2-59"';8-%/40-("@"8%')%'4-("
A"B-/%("C$;$6/40-"D-/%*'*7+"E'(-/(-"($%0-'66/*3-"/*1"'*2-34)*"3)*5%)6"()6$4)*(<"
F "G)()3);'/6"3/(-";/*/7-;-*5"F "H$5);/5-1"./*1".97'-*-"3);86'/*3-";)*'5)%'*7"F "H$5);/5-1")$5I%-/J"3)*5/35"5%/3'*7""F "K>)5L(8)5M"'1-*4N3/4)*"F "O-/6L4;-"@"($(5/'*-1"5%/3J'*7:"/6-%5("@";-5%'3("
!"
3
Incremental innovation tends to be ‘evolutionary’. Small improvements in existing practices.!
Disruptive innovation improves a product or service in ways that the market does not expect and looks to make significant impacts.!
Goal in healthcare is affordability/sustainability while increasing accessibility, quality and safety. This sector should be an ideal target for disruptive solutions.!
Innovation in Healthcare...!
P"
Open Innovation!
• C)*0-%7-*3-"Q)6$4)*"• R/%5*-%("S'5."H6'7*-1"=)/6("• C)*N%;"&'(')*"/*1"R/5."
• T/'*5/'*"5.-"&'()*"
• =-5M-%"E)*-"
!"#$%&"'()*+",-"./&-"0--,1$2,-"
34&"'5#"
'5#6",/&-"$77&%%"%70&-7&"• 8,9:&*"0-";<<="(,">&-&9$(&"?-,@A&*>&"$B,)("4):$-"/9,(&0-%"
• C&%)A(%"$-*"9&$>&-(%"0-(,"/)BA07"*,:$0-"@0(4,)("9&%(9072,-"
• D,"-,("EA&"F,9"GH",-"$-+"9&%)A(%"
• =<I",F">A,B$A",)(/)(",F"-&@"4):$-"$-*"/$9$%0(&"/9,(&0-"%(9)7()9&%"
• ;"/$/&9%"/&9"@&&?"
!"/)BA07J/901$(&"/$9(-&9%40/"
H4$9:$"
K&AA7,:&"39)%("
#$-$*$"
'@&*&-"
.-($90,"
Industrial focus yields HQP
Former SGC members:
• > 65 scientists went on to jobs in academia • 15 to leadership positions (7 Faculty positions)
• > 33 to industry (9 to leadership positions) • 7 returned to the SGC/or relocated to another SGC site • 4 to business schools
Training at SGC:
• 187 external scientists trained at the SGC (20 coop students)
No IP facilitates collaboration • More than 200 Collaborations in 17 countries world wide • ~250 publications – an average of 3.1 non-SGC scientists per paper
1 collaboration
2-5 collaborations
5-10 collaborations
10-20 collaborations
> 20 collaborations
>1000 expression clones have been sent out during the past 3 years of which more than 800 to academia
Knowledge transfer • Over the last 3 years SGC scientists attended >250 conferences the majority of them as speakers
• Serve on SAB’s of 5 biotech companies; 3 research consortia and 2 funding agencies • The SGC organised 20 workshops/conferences during the past three years
• More than 50 face-to-face meetings with industry per year
• More than 100 external scientists attended workshops held at SGC
Technology development
Testing and Improvement of a number of different products/machines in collaboration with vendors: Crystallisation:
! JCSG+ crystallization screen ! Mosquito crystallization robot ! Minstrel imaging robot ! Actor anti-icing lid ! SpearLab Liquid nitrogen handling dewars Compound screening ! Stratagene/Agilent RT-PCR ! Stargazer ! BMG Labtech multi-functional plate reader "Polarstar Omega“ ! Biacore with GE Healthcare Other ! Contur ELN
SGC driven developments: ! Lex System ! BeeHive (w. MolSoft, Inovacia, CPR) ! iSee (MolSoft) ! Software for domain boundary analysis ! Expression clone generating platform ! Phage-resistant bacterial host strains ! Proximity assay !
Commercialization
Harbinger Biotech, founded in 2005, has sold equipment to over 30 labs in industry and academia in Asia, North America and Europe
SGC software programs distributed to >40 labs
1DegreeBio founded in 2010
G-*)%(9+"H)BA07"D,:$0-"
H)BA07LH901$(&"H$9(-&9%40/"
Chemical Probes
Screening Chemistry Structure Bioavailability
Target Validation
No IP No restrictions Publication
Drug Discovery
(re)Screening Chemistry Lead optimization Pharmacology DMPK Toxicology Chemical development Clinical development
Moving the Pre-Competitive Boundary
Creative commons Proprietary
Impact of novel BET probe
250+ labs across the globe
Identified Jan 10
Published Sep 10
Distributed Jan 11
top related